Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19934140 | 0.87 | MEN1 (0.64) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL21343528 | 0.85 | MEN1 (0.68) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL26226060 | 0.84 | CASP2 (0.55) | CA12CA14TSHRCA7CA9 | |
| SCHEMBL27972232 | 0.84 | TSHR (0.55) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL5571264 | 0.83 | KMT2A (0.52) | MEN1KMT2A | |
| SCHEMBL18376239 | 0.82 | TSHR (0.52) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL22345533 | 0.80 | TSHR (0.50) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL14902247 | 0.80 | MGAM (0.52) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL18404145 | 0.80 | LMNA (0.52) | MEN1KMT2ACA12CA14TSHR | |
| SCHEMBL5839443 | 0.80 | TSHR (0.52) | MEN1KMT2ACA12CA14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | claimed |
| WO-2014031901-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | disclosed |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | RAJASEKHAR VIJAYKUMAR (US) | 2019-11-05 | — | — | US | disclosed |
| US-20170216242-A1 | METHODS OF TREATING HEART FAILURE DISEASES USING PRODRUGS OF METHYL HYDROGEN FUMARATE | RAJASEKHAR VIJAYKUMAR (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016182898-A1 | METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF | XENOPORT, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| CN-100488510-C | Morpholine derivatives as dopamine agonists in the treatment of sexual dysfunction | PFIZER (US) | 2009-05-20 | — | — | CN | disclosed |
| CN-101117335-A | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction | PFIZER (US) | 2008-02-06 | — | — | CN | disclosed |
| CN-1723023-A | Morpholine derivatives as dopamine agonists in the treatment of sexual dysfunction | PFIZER (US) | 2006-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MEN1 1064/4885KMT2A 3392/4885CA12 3884/4885 |
| US-10945984-B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | FH, FAH, ALDOA | MEN1 1212/4885KMT2A 578/4885CA12 481/4885 |
| US-10463642-B2 | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate | FH, HMGCR, HPGD | MEN1 2286/4885KMT2A 1017/4885CA12 1457/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | MEN1 1620/4885KMT2A 438/4885CA12 1057/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MEN1 887/4885KMT2A 242/4885CA12 1323/4885 |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | MEN1 4484/4885KMT2A 3228/4885CA12 3614/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | MEN1 1212/4885KMT2A 578/4885CA12 481/4885 |
| US-20170216242-A1 | METHODS OF TREATING HEART FAILURE DISEASES USING PRODRUGS OF METHYL HYDROGEN FUMARATE | FH, HMGCR, HPGD | MEN1 2286/4885KMT2A 1017/4885CA12 1457/4885 |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | IDO1, INMT, AZI2 | MEN1 1241/4885KMT2A 957/4885CA12 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.